Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“Rapid Review of our ASH25 updated results combining immunotherapy with standard chemo showing YEARS of durable complete remission for many patients with aggressive lymphoma.”
More posts about ASH25.